| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8682088 | Clinical Neurology and Neurosurgery | 2016 | 4 Pages |
Abstract
We confirmed that a) clinical IIH symptoms are suspended during octreotide exposure; b) 6-month administration can sustainably abolish IIH symptoms; c) desensitization is possible for octreotide allergy. When IIH symptoms reoccur after limited-time octreotide administration, re-application of formerly ineffective carbonic anhydrase inhibitors can suspend IIH symptoms. Intramuscular octreotide is a promising long-term therapy option.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Patrick M. (Dr. med.), Stefan R.G. (Dr. med.),